Omega-3 Index is Directly Associated with a Healthy Red Blood Cell Distribution Width

Michael I. McBurney[1-3], Nathan L. Tintle[1,4], and William S. Harris[1,5]

[1]Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); [2]Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada (MIM), [3]Division of Biochemical and Molecular Biology, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA 02111, USA (MIM); [4]Department of Population Health Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL 60612, USA(NLT); [5]Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA (WSH).

Authors' last names: McBurney, Tintle, Harris

Corresponding author: M.I. McBurney, Department of Human Health & Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada. E-mail: mim@faresinst.com

Reprint requests: W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail: wsh@faresinst.com

Sources of Support: This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health. Pending application and approval, data described in the manuscript, code book, and analytic code will be made available upon request to the Fatty Acid Research Institute (https://www.faresinst.org/).

Abbreviations: BMI, body mass index; CRP, high-sensitivity C-reactive protein; CV, coefficient of variation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Hb, hemoglobin; MCV,

24 mean corpuscular volume; O3I, omega-3 index; RBC, red blood cells. RDW, red blood cell

25 distribution width; SD, standard deviation.

26

Summary

Low red blood cell (RBC) membrane content of EPA and DHA, i.e., the omega-3 index (O3I), and elevated RBC distribution width (RDW) are risk factors for all-cause mortality. O3I and RDW are related with membrane fluidity and deformability. Our objective was to determine if there is a relationship between O3I and RDW in healthy adults. Subjects without inflammation or anemia, and with values for O3I, RDW, high-sensitivity C-reactive protein (CRP), body mass index (BMI), age and sex were identified (n=25,485) from a clinical laboratory dataset of >45,000 individuals. RDW was inversely associated with O3I before and after (both $p<0.00001$) adjusting models for sex, age, BMI and CRP. Stratification by sex revealed a sex-O3I interaction with the RDW-O3I slope ($p<0.00066$) being especially steep in females with O3I ≤5.6%. In healthy adults of both sexes, the data suggested that an O3I of >5.6% may help maintain normal RBC structural and functional integrity.

Keywords: hematology, red blood cells, omega-3 index, eicosapentaenoic acid, docosahexaenoic acid

44 **1. Introduction**

45 Mean red blood cell (RBC) corpuscular volume (MCV) and reticulocyte count were the
46 principal metrics traditionally used to identify anemic disorders until the advent of automated
47 blood cell analyzers that could routinely measure the types and distribution of blood cells.
48 Among these metrics is the RBC distribution width (RDW) [1] which reflects RBC size
49 heterogeneity. High RDW values are associated with decreased deformability [2] and RDW is
50 used to diagnose sickle cell [3] and nutritional anemias (iron, folic acid and vitamin B12) [1,4,5].
51 In recent years, RDW has been found to be a predictor of multiple adverse health outcomes
52 unrelated to anemia, including increased risk for death from cardiovascular disease [6–12],
53 SARS-CoV-2 [13–15], sepsis [16,17], lung disease [18], and cancer [19,20].

54 Like all cell membranes, RBC membranes are a complex lipid bilayer composed of
55 glycerolipids, sphingomyelin and cholesterol [21]. Fatty acids are major components of the
56 former two and contribute to the structural integrity and function of cell membranes. In
57 particular, the membrane content of omega-3 fatty acids, EPA and DHA, the sum of which is
58 called the omega-3 index (O3I) [22], increases with omega-3 fatty acid intake [23,24] and
59 affects cell deformability [25–28]. The O3I is a stable biomarker of long term EPA and DHA
60 intake [24,29]. Since both a low O3I [30] and an elevated RDW [7,31,32] are known to be
61 associated with risk for earlier all-cause mortality (**Supplemental Table 1**), the aim of this cross-
62 sectional analysis was to determine if there was an inverse relationship between the O3I and
63 RDW in healthy adults without evidence of inflammation or tissue injury. If there was, then the
64 former may play a role in maintaining a healthy distribution of RBC sizes in adults.

65

66 **2. Patients and Methods**

67 This was a cross-sectional analysis of data from blood samples submitted for testing to
68 Health Diagnostic Laboratory, Inc (HDL, Inc., Richmond VA) as part of routine clinical
69 assessment between 2011-2012. Data on RBC structural characteristics, i.e., MCV and RDW,
70 along with hemoglobin (Hb), high-sensitivity C-reactive protein (CRP) and O3I were extracted
71 from 45,715 adults (≥18 years) without any linked patient identifiers except age, sex and BMI
72 (**Supplemental Table 2**). Next, 598 individuals with O3I values in the bottom and top 0.5% of
73 the population were excluded (n=45,257). Since inflammation affects erythropoiesis, modulates
74 RBC life span, and increases RDW [33], 14,329 individuals with chronic inflammation (CRP
75 >3mg/L) [34–38] were excluded. Similarly, anemia also increases RDW [1,39], and so individuals
76 with MCV >100 fL and low Hb (Hb <13 g/dL for men and Hb <12 g/dL for women [40] were also
77 excluded (**Figure 1**). This resulted in a final, analytical dataset of 25,485 individuals (49.7%
78 female) without laboratory evidence of anemia or active infection, tissue injury, or
79 inflammation (**Table 1**).

80 *2.1 Laboratory methods*

81 Blood samples were drawn after an overnight fast and shipped with cold packs to HDL, Inc.
82 for analysis with a Beckman-Coulter DxH 800 hematology analyzer (Brea, CA, USA). Samples
83 were prepared at each clinical site according to standardized instructions as previously
84 described [41]. RDW is the SD of the RBC volume divided by the MCV multiplied by 100 [39].
85 For fatty acid analysis, RBCs were separated from plasma by centrifugation and analyzed using
86 gas chromatography as previously described [42]. The University of South Dakota Institutional

87 Review Board reviewed and approved the analysis of deidentified HLD, Inc. laboratory data
88 (IRB-21-147).

89 *2.2 Statistical methods*

90 Sample characteristics were summarized using standard statistical methods (e.g., means,
91 SDs, correlations) with t-tests or adjusted linear models used to compare characteristics of male
92 and female participants above and below O3I values that were ultimately identified as primary
93 cut points in the RDW-O3I curves (see below). Splines were fit using 3rd degree polynomials
94 with knots at each decile in R (version 3.6.2; splines package). Unadjusted models used a linear
95 model to predict RDW values by splines of O3I. Adjusted models accounted for sex, age, BMI
96 and CRP values in the linear models accounting for potential non-linear relationships using
97 splines.

98 In order to identify significant changes in the shape of the RDW-O3I relationship, we used a
99 "sliding O3I window" approach. The width of each window was three O3I percentage points
100 (e.g., 3% to 6%). By moving the window up by 0.1% increments and repeatedly testing for
101 significant differences between the mean RDW in the lower vs. the upper half of the window,
102 we sought to discover O3I cut points where the RDW-O3I relationship appeared to flatten.
103 These would be O3I values above which the "effect" of an increase in O3I on RDW had little
104 impact. We began with a window midpoint of O3I =2.6%, and we used adjusted linear models in
105 R to test for upper vs lower half differences. We identified the first window which did not have
106 a statistically significant difference in upper and lower mean RDW values. The midpoint of this
107 window was chosen as the O3I cut point to be used in further analysis. To evaluate the
108 potential moderating effect of sex on the O3I relationship with RDW, MCV, Hb, CRP, BMI and

age, we inserted an interaction term into the relevant, adjusted model. Pearson correlations were used to assess strength and direction of linear association between covariates and RDW. Statistical significance was set to 0.05 for all analyses and 95% confidence bands are provided where appropriate.

3. Results

The final dataset included 25,485 individuals (**Figure 1**) without acute inflammation or anemia. Mean BMI, O3I, MCV, Hb, and CRP values differed significantly between males and females in adjusted models (**Table 1**). RDW was significantly ($p<0.00001$) and inversely associated with O3I in unadjusted (**Figure 2A**) and adjusted models ($p<0.00001$) (**Figure 2B**). Pearson correlations (r) with RDW were r=0.21 (age), r=0.11 (CRP), r=0.14 (BMI), r=-0.25 (MCV), and r=-0.12 (Hb). The O3I cut point determined in the sliding window analysis, i.e. when the lower and upper half of an "O3I sliding window" yielded mean RDW values that did not significantly differ, was 5.6% (**Figure 2B**). That is, below an O3I of 5.6%, the curve was clearly steeper than it was above 5.6%. Because of significant sex differences in RDW and O3I in the adjusted model (**Table 1**), and because of the clear differences in the shapes of the RDW-O3I relationship between men and women **(Figure 2)**, we stratified by sex and by O3I (≤5.6% vs >5.6%) (**Table 2**). Within sex comparisons found significant differences between individuals with O3I ≤5.6% vs. >5.6% for all variables in the adjusted model for females and males (**Table 2**). We observed a significant sex by O3I interaction in the adjusted model for RDW and BMI with the difference in RDW below 5.6% being larger in females than males.

4. Discussion and Conclusions

131 RBCs are by far the most common cell in the body (83%), and as such, they have recently
132 been viewed as a separate organ deeply involved with homeostasis [43]. Their primary role is to
133 transport oxygen and carbon dioxide, and to accomplish this RBCs must pass through capillaries
134 whose diameter is half of their own [44]. Thus, RBCs must be highly flexible and able to
135 withstand high-shear stress. Here, we report an inverse relationship between the percentage of
136 omega-3 fatty acids in RBC membranes and the distribution of RBC sizes in a generally healthy
137 (i.e., not anemic and without inflammation) cohort (**Figure 2**), as well as an interaction with sex
138 (**Figure 3**). An elevated RDW was associated with O3I ≤5.6% (**Figure 2; Table 2**).
139 Changes in saturated and unsaturated fatty acid composition in cell membranes affect
140 membrane fluidity [45–47] and deformability [28,48]. EPA and DHA have specific biophysical
141 properties that affect the properties of membranes enriched in them [49]. Among these
142 properties are fluidity, deformability, and susceptibility to aggregation of RBCs [26,28].
143 Increases in membrane DHA (a highly flexible molecule) influence the flexibility and structural
144 integrity, i.e. lipid-protein interactions, of RBC membranes [50]. Increasing EPA intake alone or
145 EPA+DHA together increases RBC membrane fluidity [48] and RBC deformability [25–27,51].
146 RBC deformability is affected by membrane lipid composition and lipid-protein interactions, and
147 reduced deformability is a characteristic of aged RBCs [52]. Since an elevated RDW is likewise
148 associated with decreased RBC membrane flexibility [2], one possible explanation for our
149 findings is that a reduced EPA+DHA content of RBC membranes is causing the elevation in RDW.
150 An elevated RDW can also be caused by disordered erythropoiesis and/or RBC clearance
151 [53]. A delay in clearance allows smaller RBCs to continue circulating, increasing the average
152 age (lifespan) of RBC, and contributes to increased RDW [2]. Oxidative stress is a characteristic

153 of aging, malnutrition, inflammation, and the pathogenesis of chronic disease [54]. Oxidative
154 stress changes cytoskeletal arrangement and contributes to lipid asymmetry, causing
155 erythrocytes lose flexibility and RDW to increase [55]. A systematic review and meta-analysis of
156 39 clinical trials (2,875 participants) found omega-3 supplementation improved antioxidant
157 stability by significantly increasing serum total antioxidant capacity and decreasing serum
158 glutathione peroxidase and malondialdehyde concentrations [56]. This represents another
159 means by which omega-3 fatty acids could improve the RDW.

160 Alternatively, there may be a connection between omega-3, inflammation and the RDW.
161 Inflammation marked by elevated CRP, interleukin-6, etc. can suppress RBC maturation in bone
162 marrow, and larger immature RBCs, i.e. reticulocytes, enter the circulation and increase the
163 RDW [16]. This relationship between RDW and inflammation may partially explain the
164 relationship of higher RDW with risk of cardiovascular disease and mortality
165 [10,11,14,30,32,57]. Similarly, lower omega-3 fatty acid levels are associated with a heightened
166 inflammatory state [58–60], and omega-3 supplementation lowers inflammatory mediators
167 [61]. Thus, a possible explanation of our findings may be that higher omega-3 fatty acid levels
168 (O3I >5.6%) lower inflammatory markers which thereby lowers the RDW.

169 Because of its cross-sectional nature, we cannot draw causal inferences from these data.
170 However, there is evidence that raising RBC membrane omega-3 content can improve RDW. In
171 patients with sickle cell disease, RBC rheological disturbances, hemolysis, and abnormalities of
172 membrane fatty acids, have been ameliorated by omega-3 fatty acid treatment [62,63].
173 Supplementation with both EPA alone or EPA+DHA lowered RDW values in patients with
174 coronary heart disease [51,64] and with abdominal aortic aneurysm [65]. In the latter study,

175 supplementation increased O3I from ~4.5% to 8% and decreased RDW from 14.8% to 13.8%.
176 So, one of the mechanisms underlying the health benefits of EPA and DHA could be via an
177 improved RDW.

178 The primary strength of this study was its large sample size which enabled us to explore
179 RDW and O3I relationships in healthy individuals (males and females separately) free of
180 laboratory signs of anemia or inflammation. The most obvious limitations of this study, besides
181 its cross-sectional nature, was the lack of information on confounding metabolic events, dietary
182 behaviors, medications, other medical conditions and/or physical activities that might have also
183 been associated with O3I and with RDW. Another potential limitation is that these data were
184 drawn from a clinical laboratory database, not a formal national survey, so the
185 representativeness of these patients to healthy US adults is not clear. However, previous
186 studies in this specific cohort found that standard risk biomarkers (cholesterol, glucose, etc.)
187 generally reflected those of typical adults living in the United States examined in Nutrition And
188 Health Examination Surveys (NHANES) [66]. Also, O3I values were similar to those from a
189 representative US sample [67], and RDW, MCV, and Hb were within normal ranges [7,68,69].
190 These considerations suggest this cohort was generally representative of the US population.
191 The mean serum EPA+DHA concentration for adults 20+ years from NHANES was 2% [67] which
192 is equivalent to an O3I of about 4.8%. Hence, roughly half of Americans have an O3I <5%, i.e.,
193 the range where higher RDW may be more common.

194 In conclusion, low O3I levels (≤5.6%) were associated with a potentially unhealthy
195 distribution of RBC cell sizes. This suggests a role for EPA+DHA in maintaining RBC structure in
196 healthy individuals. We propose that achieving an O3I >5.6% could help maintain a normal RBC

size distribution. Our finding complements evidence that a higher O3I is linearly and inversely associated with risk for death from any cause [30], with values of >8% characterizing the lowest risk population [70]. Numerous researchers have called for the establishment of Dietary Reference Intake (DRI) for EPA+DHA [71–73]. To that end, our observations that maintaining an RBC EPA+DHA percentage above 5.6% may help maintain a normal RDW, could provide the scientific basis for a DRI.

Disclosures: M.I. McBurney serves on the Board of Directors of the American Society for Nutrition and has or has held consulting agreements in the past 3 years with Council for Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences Institute, North America; McCormick; OmegaQuant Analytics; PepsiCo; and VitaMe Technologies. W.S. Harris holds an interest in OmegaQuant Analytics, a lab that offers omega-3 blood testing; and is a member of the RB Schiff Science and Innovation Advisory Board. N.L. Tintle has no conflicts to disclose.

Funding: This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health.

CReditT authorship contribution statement: M.I. McBurney: Conceptualization & analytical design, Writing - original draft, Writing - review & editing. **W.S. Harris**: Conceptualization & analytical design, Funding - acquisition, Writing- review & editing. **N.L. Tintle**: Formal analysis, Writing - review & editing.

Acknowledgements: The authors wish to thank Dr. Patrick Moriarty, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS for the initial suggestion to explore the relationship between omega-3 status and RDW. We also are indebted to Steven Varvel, PhD for his help in acquiring and collating the dataset used in this study.

223 **References**

224 [1] J.D. Bessman, P.R. Gilmer, F.H. Gardner, Improved Classification of Anemias by MCV and
225 RDW, Am J Clin Pathol. 80 (1983) 322–326. https://doi.org/10.1093/ajcp/80.3.322.
226 [2] K.V. Patel, J.G. Mohanty, B. Kanapuru, C. Hesdorffer, W.B. Ershler, J.M. Rifkind, Association
227 of the Red Cell Distribution Width with Red Blood Cell Deformability, in: W.J. Welch, F.
228 Palm, D.F. Bruley, D.K. Harrison (Eds.), Oxygen Transport to Tissue XXXIV, Springer New
229 York, New York, NY, 2013: pp. 211–216. https://doi.org/10.1007/978-1-4614-4989-8_29.
230 [3] D.J. Schweiger, Red cell distribution width in sickle cell anemia, Am J Med Technol. 47
231 (1981) 231–233.
232 [4] R.O. Wallerstein, Laboratory Evaluation of Anemia, West J Medicine. 146 (1987) 443–451.
233 [5] W.G. Thompson, T. Meola, M. Lipkin, M.L. Freedman, Red Cell Distribution Width, Mean
234 Corpuscular Volume, and Transferrin Saturation in the Diagnosis of Iron Deficiency, JAMA
235 Intern. Med. 148 (1988) 2128–2130.
236 [6] M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer, Relation between Red Blood
237 Cell Distribution Width and Cardiovascular Event Rate in People with Coronary Disease,
238 Circulation. 117 (2008) 163–168. https://doi.org/10.1161/CIRCULATIONAHA.107.727545.
239 [7] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, J.K. Ghali, Gender and Ethnic
240 Differences in Red Cell Distribution Width and Its Association With Mortality Among Low
241 Risk Healthy United State Adults, The American Journal of Cardiology. 109 (2012) 1664–
242 1670. https://doi.org/10.1016/j.amjcard.2012.01.396.
243 [8] B.F. Makhoul, A. Khourieh, M. Kaplan, F. Bahouth, D. Aronson, Z.S. Azzam, Relation
244 between changes in red cell distribution width and clinical outcomes in acute

245 decompensated heart failure, Int J Cardiol. 167 (2013) 1412–1416.
246 https://doi.org/10.1016/j.ijcard.2012.04.065.
247 [9] N. Li, H. Zhou, Q. Tang, Red Blood Cell Distribution Width: A Novel Predictive Indicator for
248 Cardiovascular and Cerebrovascular Diseases, Disease Markers. 2017 (2017) 1–23.
249 https://doi.org/10.1155/2017/7089493.
250 [10] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution
251 width and risk of cardiovascular mortality: Insights from National Health and Nutrition
252 Examination Survey (NHANES)-III, Int. J. Cardiol. 232 (2017) 105–110.
253 https://doi.org/10.1016/j.ijcard.2017.01.045.
254 [11] S. Huang, Q. Zhou, N. Guo, Z. Zhang, L. Luo, Y. Luo, Z. Qin, L. Ge, Association between red
255 blood cell distribution width and in-hospital mortality in acute myocardial infarction,
256 Medicine. 100 (2021) e25404. https://doi.org/10.1097/MD.0000000000025404.
257 [12] D. Lazzeroni, L. Moderato, P.L. Marazzi, C. Pellegrino, E. Musiari, P. Castiglioni, U.
258 Camaiora, M. Bini, S. Geroldi, L. Brambilla, V. Brambilla, P. Coruzzi, Red blood cell
259 distribution width as a novel prognostic marker after myocardial revascularization or
260 cardiac valve surgery, Sci Rep. 11 (2021) 7889. https://doi.org/10.1038/s41598-021-
261 87075-4.
262 [13] B.H. Foy, J.C.T. Carlson, E. Reinertsen, R. Padros I. Valls, R. Pallares Lopez, E. Palanques-
263 Tost, C. Mow, M.B. Westover, A.D. Aguirre, J.M. Higgins, Association of Red Blood Cell
264 Distribution Width with Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection,
265 JAMA Network Open. 3 (2020) e2022058.
266 https://doi.org/10.1001/jamanetworkopen.2020.22058.

267 [14] J.L. Rapp, D. Tremblay, N. Alpert, W. Lieberman-Cribbin, J. Mascarenhas, E. Taioli, S.
268 Ghaffari, Red cell distribution width is associated with mortality in non-anemic patients
269 with COVID-19, J Med Virol. (2021) jmv.27011. https://doi.org/10.1002/jmv.27011.
270 [15] Z. Wang, Y.-W. Lin, X. Wei, F. Li, X.-L. Liao, H. Yuan, D. Huang, T. Qin, H. Geng, S. Wang,
271 Predictive Value of Prognostic Nutritional Index on COVID-19 Severity, Front. Nutr. 7
272 (2021) 582736. https://doi.org/10.3389/fnut.2020.582736.
273 [16] E. Dalbaşı, Ö.L. Akgül, Are average platelet volume, red cell distribution width and platelet
274 distribution width guiding markers for acute appendicitis treatment options?, Int J Clin
275 Pract. (2021). https://doi.org/10.1111/ijcp.14232.
276 [17] Y. Li, Y. She, L. Fu, R. Zhou, W. Xiang, L. Luo, Association Between Red Cell Distribution
277 Width and Hospital Mortality in Patients with Sepsis, J Int Med Res. 49 (2021)
278 030006052110042. https://doi.org/10.1177/03000605211004221.
279 [18] H. Go, H. Ohto, K.E. Nollet, K. Sato, H. Ichikawa, Y. Kume, Y. Kanai, H. Maeda, N.
280 Kashiwabara, K. Ogasawara, M. Sato, K. Hashimoto, M. Hosoya, Red cell distribution width
281 as a predictor for bronchopulmonary dysplasia in premature infants, Sci Rep. 11 (2021)
282 7221. https://doi.org/10.1038/s41598-021-86752-8.
283 [19] Y. Koma, A. Onishi, H. Matsuoka, N. Oda, N. Yokota, Y. Matsumoto, M. Koyama, N. Okada,
284 N. Nakashima, D. Masuya, H. Yoshimatsu, Y. Suzuki, Increased Red Blood Cell Distribution
285 Width Associates with Cancer Stage and Prognosis in Patients with Lung Cancer, PLoS ONE.
286 8 (2013) e80240. https://doi.org/10.1371/journal.pone.0080240.
287 [20] Q. Chen, R. Mao, J. Zhao, X. Bi, Z. Li, Z. Huang, Y. Zhang, J. Zhou, H. Zhao, J. Cai,
288 Nomograms incorporating preoperative RDW level for the prediction of postoperative

289 complications and survival in colorectal liver metastases after resection, Ann Palliat Med.
290 10 (2021) 4143–4158. https://doi.org/10.21037/apm-20-2418.
291 [21] T. Dingjan, A.H. Futerman, The fine-tuning of cell membrane lipid bilayers accentuates
292 their compositional complexity, BioEssays. (2021) 1–15.
293 https://doi.org/10.1002/bies.202100021.
294 [22] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary
295 heart disease?, Prev. Med. 39 (2004) 212–220.
296 https://doi.org/10.1016/j.ypmed.2004.02.030.
297 [23] H.M. Vidgren, J.J. Agren, U. Schwab, T. Rissanen, O. Hänninen, M.I. Uusitupa,
298 Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes
299 and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-
300 rich oil among healthy young men, Lipids. 32 (1997) 697–705.
301 [24] M.R. Flock, A.C. Skulas-Ray, W.S. Harris, T.D. Etherton, J.A. Fleming, P.M. Kris-Etherton,
302 Determinants of erythrocyte omega-3 fatty acid content in response to fish oil
303 supplementation: A dose–response randomized controlled trial, J. Am. Heart Assoc. 2
304 (2013) e000513. https://doi.org/10.1161/JAHA.113.000513.
305 [25] T. Terano, A. Hirai, T. Hamazaki, S. Kobayashi, T. Fujita, Y. Tamura, A. Kumagai, Effect of
306 oral administration of highly purified eicosapentaenoic acid on platelet function, blood
307 viscosity and red cell deformability in healthy human subjects, Atherosclerosis. 46 (1983)
308 321–331.
309 [26] I.J. Cartwright, A.G. Pockley, J.H. Galloway, M. Greaves, F.E. Preston, The effects of dietary
310 omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids,

311 erythrocyte deformabilit and blood viscosity in healthy volunteers, Atherosclerosis. 55
312 (1985) 267–281.
313 [27] R. Bach, U. Schmidt, F. Jung, H. Kiesewetter, B. Hennen, E. Wenzel, H. Schieffer, L. Bette, S.
314 Heyden, Effects of Fish Oil Capsules in Two Dosages on Blood Pressure, Platelet Functions,
315 Haemorheological and Clinical Chemistry Parameters in Apparently Healthy Subjects, Ann
316 Nutr Metab. 33 (1989) 359–367. https://doi.org/10.1159/000177559.
317 [28] E. Hessel, J.J. Agren, M. Paulitschke, O. Hanninen, A. Hanninen, D. Lerche, Freshwater fish
318 diet affects lipid composition, deformability and aggregation properties of erythrocytes,
319 Atherosclerosis. 82 (1990) 37–42.
320 [29] R.E. Walker, K.H. Jackson, N.L. Tintle, G.C. Shearer, A. Bernasconi, S. Masson, R. Latini, B.
321 Heydari, R.Y. Kwong, M. Flock, P.M. Kris-Etherton, A. Hedengran, R.M. Carney, A. Skulas-
322 Ray, S.S. Gidding, A. Dewell, C.D. Gardner, S.M. Grenon, B. Sarter, J.W. Newman, T.L.
323 Pedersen, M.K. Larson, W.S. Harris, Predicting the effects of supplemental EPA and DHA
324 on the omega-3 index, Am. J. Clin. Nutr. 110 (2019) 1034–1040.
325 https://doi.org/10.1093/ajcn/nqz161.
326 [30] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé,
327 J.K. Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A.
328 Murphy, C. Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G.
329 Eiriksdottir, N.G. Forouhi, J.M. Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R.
330 Jackson, K.-T. Khaw, M. Laakso, H. Lai, D. Laurin, J. Lindsay, R. Micha, J. Mursu, T.
331 Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G. Robinson, A.H. Shadyab, L. Snetselaar, A.
332 Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham, A.C. Wood, J.H.Y. Wu, F. Hu, Q.

333 Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty Acids and Outcomes
334 Research Consortium, Blood n-3 fatty acid levels and total and cause-specific mortality
335 from 17 prospective studies, Nature Commun. 12 (2021) 1–9.
336 https://doi.org/10.1038/s41467-021-22370-2.
337 [31] C. Fava, F. Cattazzo, Z.-D. Hu, G. Lippi, M. Montagnana, The role of red blood cell
338 distribution width (RDW) in cardiovascular risk assessment: useful or hype?, Ann. Transl.
339 Med. 7 (2019) 581–581. https://doi.org/10.21037/atm.2019.09.58.
340 [32] P.M. Moriarty, P.G. Steg, L.K. Gorby, A.M. Zeiher, H.D. White, T. Sourdille, M.T. Roe, M.J.
341 Louie, J.W. Jukema, R.A. Harrington, S.G. Goodman, R. Diaz, V.A. Bittner, D.L. Bhatt, M.
342 Szarek, Q.H. Li, G.G. Schwartz, Relation of Red Blood Cell Distribution Width to Risk of
343 Major Adverse Cardiovascular Events, Death, and Effect of Alirocumab After Acute
344 Coronary Syndrome, in: American Heart Association, American Heart Association,
345 Phildadelphia, PA, 2019: p. 1.
346 [33] J. Lappegård, T. Ellingsen, K. Hindberg, E. Mathiesen, I. Njølstad, T. Wilsgaard, M.-L.
347 Løchen, S. Brækkan, J.-B. Hansen, Impact of Chronic Inflammation, Assessed by hs-CRP, on
348 the Association between Red Cell Distribution Width and Arterial Cardiovascular Disease:
349 The Tromsø Study, TH Open. 02 (2018) e182–e189. https://doi.org/10.1055/s-0038-
350 1651523.
351 [34] M.A. Zimmerman, Diagnostic Implications of C-Reactive Protein, Arch Surg. 138 (2003)
352 220. https://doi.org/10.1001/archsurg.138.2.220.
353 [35] A. Villaseñor, S.W. Flatt, C. Marinac, L. Natarajan, J.P. Pierce, R.E. Patterson, Postdiagnosis
354 C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study, Cancer

355 Epidemiol Biomarkers Prev. 23 (2014) 189–199. https://doi.org/10.1158/1055-9965.EPI-
356 13-0852.
357 [36] WHO, C-reactive protein concentrations as a marker of inflammation or infection for
358 interpreting biomarkers of micronutrient status., World Health Organization, Geneva,
359 Switzerland, 2014.
360 http://apps.who.int/iris/bitstream/10665/133708/1/WHO_NMH_NHD_EPG_14.7_eng.pdf
361 ?ua=1.
362 [37] M.L. Knight, The Application of High-Sensitivity C-Reactive Protein in Clinical Practice: A
363 2015 Update, US Pharmacist. 40 (2015) 50–53.
364 [38] S. Jafarnejad, V. Boccardi, B. Hosseini, M. Taghizadeh, Z. Hamedifard, A Meta-analysis of
365 Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and
366 Serum hs-CRP Concentrations, (2018).
367 https://doi.org/10.2174/1381612824666181017101810.
368 [39] T.C. Evans, D. Jehle, The red blood cell distribution width, J. Emerg. Med. 9 (1991) 71–74.
369 https://doi.org/10.1016/0736-4679(91)90592-4.
370 [40] M.D. Cappellini, I. Motta, Anemia in Clinical Practice—Definition and Classification: Does
371 Hemoglobin Change With Aging?, Sem. Hematol. 52 (2015) 261–269.
372 https://doi.org/10.1053/j.seminhematol.2015.07.006.
373 [41] T.D. Dayspring, S.A. Varvel, L. Ghaedi, D.L. Thiselton, J. Bruton, J.P. McConnell, Biomarkers
374 of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718
375 patients, Journal of Clinical Lipidology. 9 (2015) 807–816.
376 https://doi.org/10.1016/j.jacl.2015.08.003.

377 [42] W.S. Harris, J.V. Pottala, R.S. Vasan, M.G. Larson, S.J. Robins, Changes in erythrocyte
378 membrane trans and marine fatty acids between 1999 and 2006 in older Americans, J.
379 Nutr. 142 (2012) 1297–1303. https://doi.org/10.3945/jn.112.158295.
380 [43] T. Nemkov, J.A. Reisz, Y. Xia, J.C. Zimring, A. D'Alessandro, Red blood cells as an organ?
381 How deep omics characterization of the most abundant cell in the human body highlights
382 other systemic metabolic functions beyond oxygen transport, Expert Review of
383 Proteomics. 15 (2018) 855–864. https://doi.org/10.1080/14789450.2018.1531710.
384 [44] R. Huisjes, A. Bogdanova, W.W. van Solinge, R.M. Schiffelers, L. Kaestner, R. van Wijk,
385 Squeezing for Life – Properties of Red Blood Cell Deformability, Front. Physiol. 9 (2018)
386 656. https://doi.org/10.3389/fphys.2018.00656.
387 [45] P.L. Else, A.J. Hulbert, Membranes as metabolic pacemakers, Clin Exp Pharmacol Physiol.
388 30 (2003) 559–564. https://doi.org/10.1046/j.1440-1681.2003.03883.x.
389 [46] T.R. Witte, A.J. Salazar, O.F. Ballester, W.E. Hardman, RBC and WBC fatty acid composition
390 following consumption of an omega 3 supplement: Lessons for future clinical trials, Lipids
391 Health Dis. 9 (2010) 31. https://doi.org/10.1186/1476-511X-9-31.
392 [47] U. Radzikowska, A.O. Rinaldi, Z. Çelebi Sözener, D. Karaguzel, M. Wojcik, K. Cypryk, M.
393 Akdis, C.A. Akdis, M. Sokolowska, The Influence of Dietary Fatty Acids on Immune
394 Responses, Nutrients. 11 (2019) 2990. https://doi.org/10.3390/nu11122990.
395 [48] T. Kamada, T. Yamashita, Y. Baba, M. Kai, S. Setoyama, Y. Chuman, S. Otsuji, Dietary
396 Sardine Oil Increases Erythrocyte Membrane Fluidity in Diabetic Patients, Diabetes. 35
397 (1986) 604–611.

398 [49] H.F. Turk, R.S. Chapkin, Membrane lipid raft organization is uniquely modified by n-3
399 polyunsaturated fatty acids, PLEFA. 88 (2013) 43–47.
400 [50] K. Gawrisch, N.V. Eldho, L.L. Holte, The structure of DHA in phospholipid membranes,
401 Lipids. 38 (2003) 445–452.
402 [51] E. Tajima, S. Abe, R. Watanabe, Y. Koyabu, F. Saito, H. Kaneda, M. Sakuma, S. Toyoda, T.
403 Inoue, Effects of purified eicosapentaenoic acid on red blood cell distribution width and
404 vascular endothelial function in patients with coronary artery disease, Vasc Fail. 1 (2017)
405 15–21. https://doi.org/10.30548/vascfail.1.1_15.
406 [52] J. Kim, H. Lee, S. Shin, Advances in the measurement of red blood cell deformability: A
407 brief review, J. Cell Biotechnol. 1 (2015) 63–79. https://doi.org/10.3233/JCB-15007.
408 [53] G.L. Salvagno, F. Sanchis-Gomar, A. Picanza, G. Lippi, Red blood cell distribution width: A
409 simple parameter with multiple clinical applications, Critical Reviews in Clinical Laboratory
410 Sciences. 52 (2015) 86–105. https://doi.org/10.3109/10408363.2014.992064.
411 [54] I. Liguori, G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, G. Testa, F.
412 Cacciatore, D. Bonaduce, P. Abete, Oxidative stress, aging, and diseases, Clin. Intervent.
413 Aging. Volume 13 (2018) 757–772. https://doi.org/10.2147/CIA.S158513.
414 [55] M. Minetti, L. Agati, W. Malorni, The microenvironment can shift erythrocytes from a
415 friendly to a harmful behavior: Pathogenetic implications for vascular diseases,
416 Cardiovascular Research. 75 (2007) 21–28.
417 https://doi.org/10.1016/j.cardiores.2007.03.007.
418 [56] J. Heshmati, M. Morvaridzadeh, S. Maroufizadeh, A. Akbari, M. Yavari, A. Amirinejad, A.
419 Maleki-Hajiagha, M. Sepidarkish, Omega-3 fatty acids supplementation and oxidative

420 stress parameters: A systematic review and meta-analysis of clinical trials,
421 Pharmacological Research. 149 (2019) 104462.
422 https://doi.org/10.1016/j.phrs.2019.104462.
423 [57] S. Ranka, S. Lahan, T. Dalia, A. Tripathi, A. Goyal, J. Sreenivasan, S. Taduru, M. Muhammed,
424 P. Moriarty, Association Between Red Cell Distribution Width and Cardiovascular
425 Outcomes – Systematic Review and Meta-Analysis, MRAJ. 9 (2021).
426 https://doi.org/10.18103/mra.v9i7.2468.
427 [58] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms
428 and clinical relevance, Bioch. Biophys. Acta: Mol Cell Biol Lipids. 1851 (2015) 469–484.
429 https://doi.org/10.1016/j.bbalip.2014.08.010.
430 [59] P.C. Calder, Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving
431 mediators: Concentrations in humans and the effects of age, sex, disease and increased
432 omega-3 fatty acid intake, Biochimie. 178 (2020) 105–123.
433 https://doi.org/10.1016/j.biochi.2020.08.015.
434 [60] J.D. Fontes, F. Rahman, S. Lacey, M.G. Larson, R.S. Vasan, E.J. Benjamin, W.S. Harris, S.J.
435 Robins, Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study
436 in a community-based cohort, Atherosclerosis. 240 (2015) 431–436.
437 https://doi.org/10.1016/j.atherosclerosis.2015.03.043.
438 [61] K. Li, T. Huang, J. Zheng, K. Wu, D. Li, Effect of Marine-Derived n-3 Polyunsaturated Fatty
439 Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α: A Meta-Analysis,
440 PLoS ONE. 9 (2014) e88103. https://doi.org/10.1371/journal.pone.0088103.

441 [62] A. Daak, A. Rabinowicz, K. Ghebremeskel, Omega-3 fatty acids are a potential therapy for
442 patients with sickle cell disease, Nat Rev Dis Primers. 4 (2018) 15.
443 https://doi.org/10.1038/s41572-018-0012-9.
444 [63] A.A. Daak, M.A. Lopez-Toledano, M.M. Heeney, Biochemical and therapeutic effects of
445 Omega-3 fatty acids in sickle cell disease, Complement. Therap. Med. 52 (2020) 102482.
446 https://doi.org/10.1016/j.ctim.2020.102482.
447 [64] M. Takahashi, M. Myojo, A. Watanabe, A. Kiyosue, K. Kimura, J. Ando, Y. Hirata, I. Komuro,
448 Effect of purified eicosapentaenoic acid on red cell distribution width in patients with
449 ischemic heart disease, Heart Vessels. 30 (2015) 587–594.
450 https://doi.org/10.1007/s00380-014-0526-3.
451 [65] L.T. Meital, M.T. Windsor, R.M.L. Ramirez Jewell, P. Young, K. Schulze, R. Magee, J.
452 O'Donnell, P. Jha, M. Perissiou, J. Golledge, T.G. Bailey, P. Brooks, C.D. Askew, F.D. Russell,
453 n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized
454 controlled trial, J. Lipid Res. 60 (2019) 1154–1163. https://doi.org/10.1194/jlr.P093013.
455 [66] E. Wolin, J. White, J.V. Pottala, M. Sasinowski, T. Dall, T.D. Dayspring, J.P. McConnell, D.M.
456 Hoefner, S.A. Varvel, D.L. Thiselton, G.R. Warnick, W.S. Harris, Comparison of
457 cardiometabolic risk biomarkers from a national clinical laboratory with the US adult
458 population, J. Clin. Lipid. 9 (2015) 817–823. https://doi.org/10.1016/j.jacl.2015.07.014.
459 [67] R.A. Murphy, P.P. Devarshi, S. Ekimura, K. Marshall, S. Hazels Mitmesser, Long-chain
460 omega-3 fatty acid serum concentrations across life stages in the USA: an analysis of
461 NHANES 2011–2012, BMJ Open. 11 (2021) e043301. https://doi.org/10.1136/bmjopen-
462 2020-043301.

463 [68] V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red
464 cell distribution width and high sensitivity C-reactive protein for coronary heart disease
465 mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES, Int.
466 J. Cardiol. 168 (2013) 5156–5161. https://doi.org/10.1016/j.ijcard.2013.07.109.
467 [69] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution
468 width and risk of cardiovascular mortality: Insights from National Health and Nutrition
469 Examination Survey (NHANES)-III, International Journal of Cardiology. 232 (2017) 105–110.
470 https://doi.org/10.1016/j.ijcard.2017.01.045.
471 [70] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, Curr Cardiol
472 Rep. 12 (2010) 503–508. https://doi.org/10.1007/s11886-010-0141-6.
473 [71] W.S. Harris, D. Mozaffarian, M. Lefevre, C.D. Toner, J. Colombo, S.C. Cunnane, J.M. Holden,
474 D.M. Klurfeld, M.C. Morris, J. Whelan, Towards establishing dietary reference intakes for
475 eicosapentaenoic and docosahexaenoic acids, J. Nutr. 139 (2009) 804S-819S.
476 https://doi.org/10.3945/jn.108.101329.
477 [72] P.M. Kris-Etherton, J.A. Grieger, T.D. Etherton, Dietary Reference Intakes for DHA and EPA,
478 PLEFA. 81 (2009) 99–104. https://doi.org/10.1016/j.plefa.2009.05.011.
479 [73] M.I. McBurney, J.B. Blumberg, R.B. Costello, M. Eggersdorfer, J.W.E. Jr, W.S. Harris, E.J.
480 Johnson, S.H. Mitmesser, R.C. Post, D. Rai, L.J. Schurgers, Beyond Nutrient Deficiency—
481 Opportunities to Improve Nutritional Status and Promote Health Modernizing DRIs and
482 Supplementation Recommendations, Nutrients. 13 (2021) 1–25.
483 https://doi.org/10.3390/nu13061844.
484

Table 1. Characteristics of the study population. Mean±SD.

Variable[1]	All (n=25,485)	Males (n=12,811)	Females (n=12,674)	Male vs Female Adjusted[2] p-value
O3I (%)	4.99±1.83	4.90±1.81	5.07±1.85	0.0003
RDW (%)	13.60±0.90	13.60±0.83	13.69±0.96	0.0002
MCV (fL)	92.45±4.27	92.33±4.25	92.57±4.28	0.36
Hb (g/dL)	14.40±1.21	15.14±1.03	13.65±0.88	<0.00001
CRP (mg/L)	1.23±0.77	1.21±0.75	1.25±0.78	<0.00001
BMI (kg/m^2)	27.7±5.3	28.8±4.8	25.6±5.5	<0.00001
Age (years)	54.3±14.8	54.1±14.4	54.4±15.2	0.077

[1]O3I, Omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

[2]Models were adjusted for age, BMI, and CRP (except when the model was predicting these variables).

485

486

Table 2. Characteristics of subjects by sex and omega-3 index (O3I) classification. (Mean±SD)

Variable[1]	Female[2] (n=12,674)		Male[3] (n=12,811)		Sex*O3I Interaction
	O3I ≤5.6% (n=8,475)	O3I >5.6% (n=4,199)	O3I ≤5.6% (n=9,037)	O3I >5.6% (n=3,774)	Adjusted[4] p-value
O3I (%)	3.99±0.86	7.26±1.32	3.94±0.86	7.21±1.33	0.47
RDW	13.64±0.98	13.52±0.90	13.60±0.84	13.59±0.80	0.00066
CRP (mg/L)	1.31±0.79	1.13±0.75	1.26±0.76	1.09±0.71	0.03
BMI (kg/m^2)	27.2±5.7	25.3±4.9	29.1±4.9	28.1±4.5	<0.00001
Age (years)	52.6±15.6	57.9±13.5	52.6±14.6	57.9±13.3	0.90

[1] O3I, omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

[2] All variables between O3I categories (≤5.6% vs >5.6%) for females were p<0.0001 in both adjusted and unadjusted analyses.

[3] All variables between O3I categories (≤5.6% vs >5.6%) for males were p<0.0001 in both adjusted and unadjusted analyses, except for unadjusted difference in RDW by O3I category, p=0.31.

[4] Model further adjusted for age, BMI, and CRP.

487

488

489 Figure 1. Analytical sample flow chart. RDW, red blood cell distribution width; O3I, omega-3
490 index; MCV, mean corpuscular cell volume; Hb, hemoglobin.
491
492 Figure 2. The unadjusted (A) and adjusted for age, sex, BMI and CRP (B) relationship between
493 the red blood cell distribution width (RDW) and omega-3 index (O3I) in 25,485 adults without
494 inflammation or anemia. (Predicted means and 95% confidence bands).
495
496 Figure 3. The unadjusted (A) and adjusted for age, BMI, and CRP (B) relationships between the
497 red blood distribution width (RDW) and omega-3 index (O3I) in 12,811 males (A) and 12,674
498 females (B) without inflammation or anemia. (Predicted means and 95% confidence bands).


45,715 adults
(18+ years with RDW, BMI, CRP, Age, Sex)
Bottom 0.5% O3I
(n=229)
Top 0.5% O3I
(n=229)
(n=45,257)
(44.9% Male)
Missing Hb
(n=253)
MCV >100 fL
(n=2,227)
Missing CRP
(n=1,055)
CRP >3 mg/L
(n=14,329)
(n=27,393)
Males
(n=13,492)
Females
(n=13,901)
Hb <13g/dL
(n=681)
Hb <12g/dL
(n=1,227)
Males
(n=12,811)
Females
(n=12,674)
(n=25,485)


A
Unadjusted
(n=25,485)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)
B
Adjusted
(n=25,485)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)


A
Adjusted Males
(n=12,811)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)
B
Adjusted Females
(n=12,674)
14.0
13.75
13.5
RDW
p<0.0001
3
6
9
O3I (%)